A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as frist-line chemotherapy for women with metastatic breast cancer

S. Cresta, G. Grasselli, M. Mansutti, A. Martoni, G. Lelli, G. Capri, F. Buzzi, G. Robustelli Della Cuna, A. Jirillo, E. Terzoli, L. Frevola, E. Tarenzi, C. Sguotti, N. Azli, M. Murawsky, L. Gianni

Research output: Contribution to journalArticle

Abstract

Background: This randomized phase II study was conducted to evaluate the efficacy of doxorubicin and docetaxel (DOC) administered either as a combination, an alternating or a sequential regimen in women with metastatic breast cancer. Secondary objectives included overall response, time to progression, survival and safety. Patients and methods: Patients with breast cancer (n = 123) were randomized to receive doxorubicin and DOC either in combination (60 mg/m2 of each drug), or by alternated or sequential schedule (100 mg/m2 DOC and 75 mg/m2 doxorubicin) every 3 weeks for a maximum of eight cycles as first chemotherapy for stage IV disease. A second randomization allocated patients from each arm to receive prophylactic oral ciprofloxacin or no therapy to prevent febrile neutropenia. Results: Patients received a median of eight cycles. In an intention-to-treat analysis, the overall response was 63%, 52% and 61% in the combination, alternating and sequential schedules, respectively. Corresponding rates of complete response were 15%, 14% and 11%. Grade 4 neutropenia was common in all arms (81%) and, together with febrile neutropenia, was significantly more frequent with the combination. Prophylaxis with ciprofloxacin did not reduce the incidence of febrile neutropenia or infection. Other frequent non-hematological adverse events included alopecia, nausea, vomiting, stomatitis and asthenia. Congestive heart failure only occurred in the combination arm (10%). Conclusion: All three schedules are feasible and endowed of good therapeutic activity. In view of the more pronounced toxicity and the risk of cardiac events because of the higher exposure to doxorubicin, the combination should be least favored when treating women with metastatic breast cancer. Prophylaxis with ciprofloxacin was ineffective and is not recommended.

Original languageEnglish
Pages (from-to)433-439
Number of pages7
JournalAnnals of Oncology
Volume15
Issue number3
DOIs
Publication statusPublished - Mar 2004

Fingerprint

docetaxel
Febrile Neutropenia
Doxorubicin
Ciprofloxacin
Breast Neoplasms
Drug Therapy
Appointments and Schedules
Asthenia
Stomatitis
Intention to Treat Analysis
Alopecia
Random Allocation
Neutropenia
Nausea
Reaction Time
Vomiting
Heart Failure
Safety
Survival
Incidence

Keywords

  • Breast cancer
  • Docetaxel
  • Doxorubicin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as frist-line chemotherapy for women with metastatic breast cancer. / Cresta, S.; Grasselli, G.; Mansutti, M.; Martoni, A.; Lelli, G.; Capri, G.; Buzzi, F.; Robustelli Della Cuna, G.; Jirillo, A.; Terzoli, E.; Frevola, L.; Tarenzi, E.; Sguotti, C.; Azli, N.; Murawsky, M.; Gianni, L.

In: Annals of Oncology, Vol. 15, No. 3, 03.2004, p. 433-439.

Research output: Contribution to journalArticle

Cresta, S, Grasselli, G, Mansutti, M, Martoni, A, Lelli, G, Capri, G, Buzzi, F, Robustelli Della Cuna, G, Jirillo, A, Terzoli, E, Frevola, L, Tarenzi, E, Sguotti, C, Azli, N, Murawsky, M & Gianni, L 2004, 'A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as frist-line chemotherapy for women with metastatic breast cancer', Annals of Oncology, vol. 15, no. 3, pp. 433-439. https://doi.org/10.1093/annonc/mdh107
Cresta, S. ; Grasselli, G. ; Mansutti, M. ; Martoni, A. ; Lelli, G. ; Capri, G. ; Buzzi, F. ; Robustelli Della Cuna, G. ; Jirillo, A. ; Terzoli, E. ; Frevola, L. ; Tarenzi, E. ; Sguotti, C. ; Azli, N. ; Murawsky, M. ; Gianni, L. / A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as frist-line chemotherapy for women with metastatic breast cancer. In: Annals of Oncology. 2004 ; Vol. 15, No. 3. pp. 433-439.
@article{589872927fc9496fb48bb3d11a704315,
title = "A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as frist-line chemotherapy for women with metastatic breast cancer",
abstract = "Background: This randomized phase II study was conducted to evaluate the efficacy of doxorubicin and docetaxel (DOC) administered either as a combination, an alternating or a sequential regimen in women with metastatic breast cancer. Secondary objectives included overall response, time to progression, survival and safety. Patients and methods: Patients with breast cancer (n = 123) were randomized to receive doxorubicin and DOC either in combination (60 mg/m2 of each drug), or by alternated or sequential schedule (100 mg/m2 DOC and 75 mg/m2 doxorubicin) every 3 weeks for a maximum of eight cycles as first chemotherapy for stage IV disease. A second randomization allocated patients from each arm to receive prophylactic oral ciprofloxacin or no therapy to prevent febrile neutropenia. Results: Patients received a median of eight cycles. In an intention-to-treat analysis, the overall response was 63{\%}, 52{\%} and 61{\%} in the combination, alternating and sequential schedules, respectively. Corresponding rates of complete response were 15{\%}, 14{\%} and 11{\%}. Grade 4 neutropenia was common in all arms (81{\%}) and, together with febrile neutropenia, was significantly more frequent with the combination. Prophylaxis with ciprofloxacin did not reduce the incidence of febrile neutropenia or infection. Other frequent non-hematological adverse events included alopecia, nausea, vomiting, stomatitis and asthenia. Congestive heart failure only occurred in the combination arm (10{\%}). Conclusion: All three schedules are feasible and endowed of good therapeutic activity. In view of the more pronounced toxicity and the risk of cardiac events because of the higher exposure to doxorubicin, the combination should be least favored when treating women with metastatic breast cancer. Prophylaxis with ciprofloxacin was ineffective and is not recommended.",
keywords = "Breast cancer, Docetaxel, Doxorubicin",
author = "S. Cresta and G. Grasselli and M. Mansutti and A. Martoni and G. Lelli and G. Capri and F. Buzzi and {Robustelli Della Cuna}, G. and A. Jirillo and E. Terzoli and L. Frevola and E. Tarenzi and C. Sguotti and N. Azli and M. Murawsky and L. Gianni",
year = "2004",
month = "3",
doi = "10.1093/annonc/mdh107",
language = "English",
volume = "15",
pages = "433--439",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as frist-line chemotherapy for women with metastatic breast cancer

AU - Cresta, S.

AU - Grasselli, G.

AU - Mansutti, M.

AU - Martoni, A.

AU - Lelli, G.

AU - Capri, G.

AU - Buzzi, F.

AU - Robustelli Della Cuna, G.

AU - Jirillo, A.

AU - Terzoli, E.

AU - Frevola, L.

AU - Tarenzi, E.

AU - Sguotti, C.

AU - Azli, N.

AU - Murawsky, M.

AU - Gianni, L.

PY - 2004/3

Y1 - 2004/3

N2 - Background: This randomized phase II study was conducted to evaluate the efficacy of doxorubicin and docetaxel (DOC) administered either as a combination, an alternating or a sequential regimen in women with metastatic breast cancer. Secondary objectives included overall response, time to progression, survival and safety. Patients and methods: Patients with breast cancer (n = 123) were randomized to receive doxorubicin and DOC either in combination (60 mg/m2 of each drug), or by alternated or sequential schedule (100 mg/m2 DOC and 75 mg/m2 doxorubicin) every 3 weeks for a maximum of eight cycles as first chemotherapy for stage IV disease. A second randomization allocated patients from each arm to receive prophylactic oral ciprofloxacin or no therapy to prevent febrile neutropenia. Results: Patients received a median of eight cycles. In an intention-to-treat analysis, the overall response was 63%, 52% and 61% in the combination, alternating and sequential schedules, respectively. Corresponding rates of complete response were 15%, 14% and 11%. Grade 4 neutropenia was common in all arms (81%) and, together with febrile neutropenia, was significantly more frequent with the combination. Prophylaxis with ciprofloxacin did not reduce the incidence of febrile neutropenia or infection. Other frequent non-hematological adverse events included alopecia, nausea, vomiting, stomatitis and asthenia. Congestive heart failure only occurred in the combination arm (10%). Conclusion: All three schedules are feasible and endowed of good therapeutic activity. In view of the more pronounced toxicity and the risk of cardiac events because of the higher exposure to doxorubicin, the combination should be least favored when treating women with metastatic breast cancer. Prophylaxis with ciprofloxacin was ineffective and is not recommended.

AB - Background: This randomized phase II study was conducted to evaluate the efficacy of doxorubicin and docetaxel (DOC) administered either as a combination, an alternating or a sequential regimen in women with metastatic breast cancer. Secondary objectives included overall response, time to progression, survival and safety. Patients and methods: Patients with breast cancer (n = 123) were randomized to receive doxorubicin and DOC either in combination (60 mg/m2 of each drug), or by alternated or sequential schedule (100 mg/m2 DOC and 75 mg/m2 doxorubicin) every 3 weeks for a maximum of eight cycles as first chemotherapy for stage IV disease. A second randomization allocated patients from each arm to receive prophylactic oral ciprofloxacin or no therapy to prevent febrile neutropenia. Results: Patients received a median of eight cycles. In an intention-to-treat analysis, the overall response was 63%, 52% and 61% in the combination, alternating and sequential schedules, respectively. Corresponding rates of complete response were 15%, 14% and 11%. Grade 4 neutropenia was common in all arms (81%) and, together with febrile neutropenia, was significantly more frequent with the combination. Prophylaxis with ciprofloxacin did not reduce the incidence of febrile neutropenia or infection. Other frequent non-hematological adverse events included alopecia, nausea, vomiting, stomatitis and asthenia. Congestive heart failure only occurred in the combination arm (10%). Conclusion: All three schedules are feasible and endowed of good therapeutic activity. In view of the more pronounced toxicity and the risk of cardiac events because of the higher exposure to doxorubicin, the combination should be least favored when treating women with metastatic breast cancer. Prophylaxis with ciprofloxacin was ineffective and is not recommended.

KW - Breast cancer

KW - Docetaxel

KW - Doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=11144356326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144356326&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdh107

DO - 10.1093/annonc/mdh107

M3 - Article

C2 - 14998845

AN - SCOPUS:11144356326

VL - 15

SP - 433

EP - 439

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -